Last updated on March 2020

Study of Nivolumab Plus Ipilimumab Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

Brief description of study

The purpose of this study is to determine whether Nivolumab plus Ipilimumab has preliminary evidence of safety and effectiveness in the treatment of participants with metastatic castration-resistant prostate cancer who have progressed after prior Docetaxel-containing regimen.

Clinical Study Identifier: NCT02985957

Find a site near you

Start Over